Inhibition of human serine proteases by substituted 2-azetidinones

Arch Biochem Biophys. 1992 Aug 1;296(2):704-8. doi: 10.1016/0003-9861(92)90630-f.

Abstract

trans-4-Ethoxycarbonyl-3-ethyl-1-(4-nitrophenyl-sulfonyl)-azetidin -3-one described by Firestone et al. (1990, Tetrahedron 46, 2255) as an inhibitor of human leucocyte elastase (HLE) displayed potent, time-dependent inhibition of both HLE and human cathepsin G (Cat-G). The cis-isomer was 7- and 180-fold less active, respectively. The mechanism likely involves opening of the beta-lactam ring by the active site serine to form an acyl-enzyme intermediate(s). This intermediate partitions with ratios of 4:1 between turnover of the inhibitor and formation of relatively stable enzyme-inhibitor complexes from both enzymes. The final HLE-inhibitor complex reactivated with a half-life of 48 h at 25 degrees C and was 16-fold more stable than the Cat-G-inhibitor complex. The stability of the acyl-enzymes supports a "double hit" chemical mechanism involving both serine acylation and alkylation of the histidine. These observations suggest that beta-lactams may be developed as a class of serine protease inhibitors.

MeSH terms

  • Azetidines / chemistry
  • Azetidines / metabolism
  • Azetidines / pharmacology*
  • Cathepsin G
  • Cathepsins / antagonists & inhibitors
  • Cathepsins / metabolism
  • Humans
  • Kinetics
  • Leukocyte Elastase
  • Pancreatic Elastase / antagonists & inhibitors
  • Pancreatic Elastase / metabolism
  • Serine Endopeptidases
  • Serine Proteinase Inhibitors / pharmacology*

Substances

  • Azetidines
  • Serine Proteinase Inhibitors
  • L 652117
  • Cathepsins
  • Serine Endopeptidases
  • CTSG protein, human
  • Cathepsin G
  • Pancreatic Elastase
  • Leukocyte Elastase